

AD_____

Award Number: DAMD17-94-J-4331

TITLE: Retrotransposons as Mutagens in Human Breast Cancer

PRINCIPAL INVESTIGATOR: Thomas G. Fanning, Ph.D.

CONTRACTING ORGANIZATION: Armed Forces Institute of Pathology
Washington, DC 20306-6000

REPORT DATE: August 2000

TYPE OF REPORT: Addendum to Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010322 161

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)**2. REPORT DATE**

August 2000

3. REPORT TYPE AND DATES COVERED

Addendum to Final (30 Sep 94 - 29 Oct 99)

4. TITLE AND SUBTITLE

Retrotransposons as Mutagens in Human Breast Cancer

5. FUNDING NUMBERS

DAMD17-94-J-4331

6. AUTHOR(S)

Thomas G. Fanning, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)Armed Forces Institute of Pathology
Washington, DC 20306-6000E-Mail: fanning@afip.osd.mil**8. PERFORMING ORGANIZATION
REPORT NUMBER****9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**10. SPONSORING / MONITORING
AGENCY REPORT NUMBER****11. SUPPLEMENTARY NOTES****12a. DISTRIBUTION / AVAILABILITY STATEMENT**

Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE**13. ABSTRACT (Maximum 200 Words)****14. SUBJECT TERMS**

Breast Cancer

15. NUMBER OF PAGES

4

16. PRICE CODE**17. SECURITY CLASSIFICATION
OF REPORT**

Unclassified

**18. SECURITY CLASSIFICATION
OF THIS PAGE**

Unclassified

**19. SECURITY CLASSIFICATION
OF ABSTRACT**

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

Addendum: Final report for award number DAMD17-94-J-4331.

Award title: LINE-1 retrotransposons as mutagens in human breast cancer.

Thomas G. Fanning

Dept. Cellular Pathology

AFIP

Washington, DC 20306

Original goal of the project.

It is known that the human LINE-1 retrotransposon (L1Hs) is transcriptionally active in many breast cancer cells. The original goal of the project was to test the possibility that L1Hs retrotransposition events result in the inactivation of tumor suppressor genes by insertional mutagenesis. A tagged L1Hs element was to be stably integrated into a nonmalignant breast cell line (MCF10A) and allowed to retrotranspose. Malignant cells would then be identified and the genes into which the L1Hs element had integrated could be isolated using the tag.

Summary of previously reported research.

To test the system constructs were made placing the first ORF of L1Hs under the control of various promoters (RSV, CMV, MMTV) in vectors having drug resistant genes. MCF10A cells were transfected using a variety of protocols, e.g., calcium phosphate-DNA coprecipitation, Lipofectin, etc. Although many drug resistant colonies were obtained, none expressed L1Hs. Other vectors, including retroviral vectors, were later tried, but with the same negative result. A bicistronic vector, pIRES1neo, did work, however, and gave rise to stable drug resistant colonies that expressed the initial ORF of L1Hs at high levels. This led us to hope that the complete, tagged L1Hs element could be similarly integrated into the genome and expressed using the bicistronic vector.

Summary of research not previously reported.

We constructed a vector, IRES101, containing the following elements: CMV promoter - complete L1Hs element containing a neo gene plus intervening sequence in reverse orientation (to detect retrotransposition events and serve as the tag) - intervening sequence - IRES sequence - hygromycin resistance gene - polyA signal. To see how well the construct would work it was transfected into HeLa cells and various combinations of, (a) time before drug treatment and, (b) TPA treatment (a phorbol ester known to enhance transcription from the CMV promoter) were tested. Retrotransposition events could be detected in a number of experiments, showing that the construct was functional. However, the numbers of retrotransposition events were orders of magnitude lower than those needed to have a realistic chance of inactivating tumor suppressor genes. In an attempt to boost the number of retrotransposition events the IRES101 vector has been modified in several ways, but these vectors have not yet been tested. Cell lines developed during the course of the project, which express L1Hs proteins under the control of the CMV promoter, may prove useful in studying the interaction(s) of L1Hs proteins with other cellular proteins.

Publications/manuscripts.

No publications or manuscripts have yet come out of this work.